A total of nine companies have been accepted into Bayer’s Digital Health Partnership Program, as recently announced on the EU Startups website.
In 2021, the pharmaceutical company was looking for young companies across Europe with expertise in the areas of mental health, cardiovascular and kidney diseases, radiology and women’s health.
WHAT’S THE IMPACT
The finalists were selected from over a hundred applications in more than 40 countries.
As Bayer announced, four new startups have now been accepted into the Digital Health Partnership Program via Bayer’s G4A Growth Track: This investment opportunity is aimed at young startups in medical fields that are currently in high demand.
According to the EU Startups website, the startups funded are:
- Cardiokol, a voice recognition-based digital telemedicine solution for monitoring and screening cardiac arrhythmias for mass populations at risk, namely the elderly.
- Acorai, a non-invasive intracardiac pressure monitoring application for patients with heart failure.
- Pollie, a personalized program for menstruating women to streamline chronic polycystic ovarian syndrome (PCOS) disorders.
- RCubeHealth, developer of RESONY, a mental health mobile app designed to better manage stress and build resilience.
Each of these startups receives 100,000 euros for the market launch together with Bayer’s mentoring and external industry coaching for market entry, finance, GDPR and HIPAA compliance.
In addition, Bayer’s G4A Advanced Track – a funding program for more experienced, medium-sized companies in the digital health sector – selected five new companies for commercial partnerships:
- Liva Healthcare, developer of a digital behavior change program with tailor-made health plans for nutrition, weight loss, coaching and group interventions for high-risk patients with and without chronic diseases.
- Cordio Medical, a digital solution for monitoring various health conditions in real time using voice samples – for the early detection of diseases.
- Nines, a pioneer in innovation in radiology.
- Woebot Health, developer of a “digital therapist,” a relational mental health agent who connects with patients.
- Zed Technologies, provider of an instant access solution for sharing X-ray images and scans via a secure platform for sharing medical images.
THE BIGGER TREND
With the investments in the above-mentioned companies, the pharmaceutical giant wants to accelerate the research and development of products and solutions in the field of digital health.
A year ago, in November 2020, the G4A Digital Health Partnership Program focused on expanding digital partnerships – back then in the fields of cardiometabolic care, oncology and women’s health.
In spring 2019, the German life science company bundled all of its funding programs in one application slot, both for young and medium-sized startups and for mature companies in the digital health sector.
The top investment priorities for the next year will be mental health, women’s health, oncology and cardiometabolic diseases. The application process in 2022 will be designed as an open cycle for the first time, so that companies with promising ideas can apply all year round – from January 2022.
Bayer’s G4A program has so far scaled and supported over 150 European health technology companies through commercial partnerships, collaborations and investments.